Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00074165 · OUTCOME

Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen · Source last updated 2023-07-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
2 years

Analysis population: Data not collected due to low accrual and early termination.

Groups in this outcome

Rituximab and Carboplatin

Rituximab: (i.v.) 375 mg/m\^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m\^2 /day x 2 days = 400 mg/m\^2

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rituximab and Carboplatin0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
groups
  1. description
    Rituximab: (i.v.) 375 mg/m\^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m\^2 /day x 2 days = 400 mg/m\^2
    id
    OG000
    title
    Rituximab and Carboplatin
population Description
Data not collected due to low accrual and early termination.
reporting Status
POSTED
time Frame
2 years
title
Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice